Form 8-K · Current Report · Filed 2024-11-04
Zoetis Reports Strong Q3 2024 Financial Results and Raises Full-Year Guidance
Zoetis Inc. reported robust financial results for the third quarter of 2024, with revenue of $2.4 billion, a 11% increase, and net income of $682 million, or $1.50 per diluted share, a 14% rise. The company also raised its full-year 2024 guidance, anticipating revenue between $9.200 billion and $9.300 billion, with adjusted diluted EPS between $5.86 and $5.92. Segment performance showed significant growth, with the U.S. segment revenue increasing by 15% and the International segment by 7%. Zoetis also completed the divestiture of its medicated feed additive portfolio, reflecting its strategic focus on core capabilities.
- Filer
- Zoetis Inc. ZTS · NYSE
- Filed
- Accession
- 0001555280-24-000330
- CIK
- 0001555280
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Market reaction
Close before filing
$181.95
Next session
-3.7%
Since filing
-57.5%
Latest close
$77.29
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ZTS reporting the same item, with the next session's move:
Exhibits (1)
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Never miss another ZTS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.